Inclusion Criteria:

- Patients must be at least 18 years of age, with adequate organ function, and an ECOG
performance of <2

- Patients must be willing to undergo pre-study and post dose tumor biopsy and have
tumor accessible to biopsy (waived during Part A)

Exclusion Criteria:

- No chemotherapy, radiotherapy, or biological therapy with 4 weeks of study
participation

- Patients must not have primary central nervous system tumor

- Patient has had prescription or non-prescription drugs or other products known to be
metabolized by CYP3A4 that cannot be discontinued prior to Day 1 of dosing and
withheld throughout the study until 2 weeks after the last dose of study medication